The effects of HPA axis function on cognition and its implications for the pathophysiology of bipolar disorder

Harvard Review of Psychiatry

Volumn 22, Issue 6, 2014, Pages 331-333

  Young, Allan H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bipolar disorder; Cognition; Dopamine; HPA axis; Pathophysiology

Indexed keywords

DOPAMINE; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE;

BIPOLAR DISORDER; BRAIN; COGNITION; DOPAMINERGIC TRANSMISSION; GENE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STRESS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; PHYSIOLOGY;

BIPOLAR DISORDER; COGNITION; DOPAMINE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; STRESS, PSYCHOLOGICAL;

EID: 84925820735     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0000000000000020     Document Type: Review

References (24)

1. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrumdisorder in the worldmental health survey initiative. Arch Gen Psychiatry 2011;68:241-51.
2. Freedman R, Lewis DA, Michels R, et al. The initial field trials of DSM-5: new blooms and old thorns. Am J Psychiatry 2013;170:1-5.
3. Sullivan PF1, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet 2012;13:537-51.
4. Risch N, Herrell R, Lehner T, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 2009;301:2462-71.
5. McGowan PO1, Sasaki A, D'Alessio AC, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009;12:342-8.
6. Watson S, Gallagher P, James C, Ritchie JC, I. Nicol Ferrier IN, Young AH. HPA axis function in patientswith bipolar disorder. Br J Psychiatry 2004;184:496-502.
7. Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF; Stanley Neuropathology Consortium. Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings fromthe Stanley Neuropathology Consortium. Mol Psychiatry 2004;9:609-20, 544.
8. Xing GQ, Russell S, Webster MJ, Post RM. Decreased expression of mineralocorticoid receptor mRNA in the prefrontal cortex in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol 2004;7:143-53.
9. Webster MJ, Fullerton JM, Weickert CS. Glucocorticoid receptor mRNA and protein isoform alterations in the orbitofrontal cortex in schizophrenia and BD. BMC Psychiatry 2012;12:84.
10. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 2008;65:1017-32.
11. Yatham LN, Liddle PF, Shiah IS, et al. PET study of [(18) F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizernaive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry 2002;159:768-74.
12. Sargent PA, et al. 5-HT (1A) receptor binding in euthymic bipolar patients using positron emission tomography with [carbonyl-(11) C] WAY-100635. J Affect Disord 2010;123(1-3):77-80.
13. Barrett SL, et al. Patterns of neurocognitive impairment in first-episode BD and schizophrenia. Br J Psychiatry 2009;195:67-72.
14. Moore GJ, Cortese BM, Glitz DA, et al. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 2009;70:699-705.
15. Angst J. Bipolar disorder-methodological problems and future perspectives. Dialogues Clin Neurosci 2008;10:129-39.
16. Rush AJ, Post RM, Nolen WA, et al. Methodological issues in developing new acute treatments for patients with bipolar illness. Biol Psychiatry 2000;48:615-24.
17. Kapczinski F, Vieta E, Andreazza AC, et al. Allostatic load in BD: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008;32:675-92.
18. Young AH, Sahakian BJ, Robbins TW, Cowen PJ. The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology (Berl) 1999;145:260-6.
19. Cousins DA, Butts K, Young AH. The role of dopamine in BD. Bipolar Disord 2009;11:787-806.
20. Butts KA, Weinberg J, Young AH, Phillips AG. Glucocorticoid receptors in the prefrontal cortex regulate stress-evoked dopamine efflux and aspects of executive function. Proc Natl Acad Sci USA 2011;108:18459-64.
21. Watson S, Thompson JM, Ritchie JC, Nicol Ferrier I, Young AH. Neuropsychological impairment in BD: the relationship with glucocorticoid receptor function. Bipolar Disord 2006;8:85-90.
22. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004;29:1538-45.
23. Watson S, Gallagher P, Porter RJ, et al. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol Psychiatry 2012;72:943-9.
24. Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E. Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol 2008;18:787-93.